Clinical Trial Update: Feasibility And Safety Study Of rhBMP-2/CPM For Hip Fractures [Phase 2]

View source ↗

Summary

This ClinicalTrials.gov update reports the completion of a Phase 2 feasibility and safety study evaluating rhBMP-2/CPM for hip fractures.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hip Fracture

Drugs mentioned

• rhBMP-2/CPM (recombinant human bone morphogenetic protein-2 with calcium phosphate matrix)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Fractures | Phase 2 | Status: COMPLETED